Polymorphically acetylated aminoglutethimide in humans

R. C. Coombes, A. B. Foster, S. J. Harland, M. Jarman, E. C. Nice

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)


The urinary excretion during 24 h of aminoglutethimide (AG) its major metabolite (N-acetylAG) and two minor metabolites (N-formylAG and nitroG) were measured in 10 volunteers given AG who had been typed for acetylator phenotype using sulphadimidine. The slow acetylators of sulphadimidine excreted more AG (mean 28% of the administered dose) than did the fast acetylators (12%), but the latter excreted more of the dose as N-acetylAG (8.8%) than did the former (3.9%). NitroG and N-formylAG were minor urinary metabolites of AG in humans. The former was more abundant in the urine of slow acetylators (0.10% of the dose) than in that of fast acetylators (0.047%), whereas the respective proportions of doses excreted as the N-formyl derivative (0.475 and 0.465%) were not significantly different for the two acetylator phenotypes. These results show that AG is among those drugs that are polymorphically acetylated in humans.

Original languageEnglish
Pages (from-to)340-345
Number of pages6
JournalBritish Journal of Cancer
Issue number3
Publication statusPublished - 1 Jan 1982
Externally publishedYes

Cite this